Fundamental analysis · SEC EDGAR · TTM through 30/06/2026
BMY · NYSE · Healthcare
Fundamental quality
77
out of 100
Bristol Myers Squibb Co runs like a cash machine: it converts about 23.3% of revenue into free cash flow and holds a 18.9% net margin, though it grows at a measured pace. On fundamental quality it scores 77 out of 100, profiling it as a company with solid fundamentals. Its weakest area is its growth (revenue +2.7%/yr). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
Bristol Myers Squibb is a big pharma focused on oncology, hematology and immunology. It's living the sector's classic transition: its legacy blockbusters are losing patent protection and must be replaced by a new generation of drugs bought and developed at great expense.
EPS growth: 8.7% · Revenue growth: 2.7%
Net margin: 18.9% · ROE: 41.6% · ROIC: 18.8%
Net debt/EBITDA: 2.03x · FCF: 23.3%
Source: SEC EDGAR · TTM through 30/06/2026
The score includes +4 for dividend strength: 18 consecutive years of increases. Keeping that streak demands growing cash generation and balance-sheet discipline.
The score combines growth, profitability and financial strength. Here its profitability weighs in its favor, while its growth drags it down the most.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2020 | 42,518 | -9,015 | 13,299 | 35,790 |
| 2021 | 46,385 | 6,994 | 15,234 | 30,390 |
| 2022 | 46,159 | 6,327 | 11,948 | 29,830 |
| 2023 | 45,006 | 8,025 | 12,651 | 28,062 |
| 2024 | 48,300 | -8,948 | 13,942 | 39,085 |
| 2025 | 48,194 | 7,054 | 12,845 | 34,618 |
Between 2020 and 2025, revenue went from $42,518M to $48,194M (+13%) and net income went from -$9,015M to $7,054M (+178%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Latest results
Figures for the half-year ended June 30, 2026, versus the half-year ended June 30, 2025 (SEC filings):
Compared with the previous close (March 31, 2026), this is what moved in its accounts:
Automatic comparison between the two most recent periods filed with the SEC. One quarter doesn't make a trend: read it alongside the historical evolution above.
$2.49
per share, yearly
71.5% of earnings
Payout
at least 18 straight years raising it
Growth
That is what we can verify in the SEC filings, whose structured data only starts in 2008 and which many companies begin tagging later. The real streak may be considerably longer.
The dividend yield depends on today's price. Compute it in the analyzer → · See all dividend-paying stocks →
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is Bristol Myers Squibb Co cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is Bristol Myers Squibb Co a good company to invest in?
In terms of business quality, Bristol Myers Squibb Co scores 77 out of 100 in our analysis, placing it as a company of high fundamental quality. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is Bristol Myers Squibb Co a profitable company?
Yes. Bristol Myers Squibb Co shows a net margin of 18.9% and an ROE of 41.6%, a sign of a profitable business.
Does Bristol Myers Squibb Co have a lot of debt?
A moderate level: its net debt is 2.03 times its EBITDA.
Is Bristol Myers Squibb Co growing?
Its revenue has grown 2.7% annualized in recent years and its earnings per share 8.7%.
Does Bristol Myers Squibb Co generate cash?
Yes. It converts about 23.3% of its revenue into free cash flow, and has done so positively year after year.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
Medtronic (MDT) · Regeneron (REGN) · Cigna (CI) · Elevance Health (ELV) · McKesson (MCK) · Zoetis (ZTS) · see more →
The best Healthcare stocks by our model →
Compare Bristol Myers Squibb Co with 500+ companies in the screener →
Who's behind the methodology and model · how the score is computed
Data: see Bristol Myers Squibb Co's filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.